Renal Cell Carcinoma (RCC)

Oncology
4
Pipeline Programs
6
Companies
6
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
1100%
+ 5 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
1
ARQ 197Phase 21 trial
Active Trials
NCT00557609Completed47Est. Feb 2011
Precision BioSciences
1 program
1
CD70-targeted CAR-T cellsPhase 1Cell Therapy1 trial
Active Trials
NCT07181720Recruiting90Est. May 2028
Celldex Therapeutics
1 program
1
CDX-014Phase 11 trial
Active Trials
NCT02837991Terminated16Est. Nov 2018
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
Chimeric monoclonal antibody cG250Phase 11 trial
Active Trials
NCT00520533Terminated8Est. Sep 2012
Siemens Healthineers
Siemens HealthineersGermany - Forchheim
1 program
Trans-arterial embolizationN/A1 trial
Active Trials
NCT05410509RecruitingEst. Dec 2027
Pfizer
PfizerNEW YORK, NY
1 program
Tyrosine kinase inhibitorN/A1 trial
Active Trials
NCT04375150Completed355Est. Oct 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Merck & Co.ARQ 197
Precision BioSciencesCD70-targeted CAR-T cells
Celldex TherapeuticsCDX-014
Heidelberg PharmaChimeric monoclonal antibody cG250
Siemens HealthineersTrans-arterial embolization
PfizerTyrosine kinase inhibitor

Clinical Trials (6)

Total enrollment: 516 patients across 6 trials

NCT00557609Merck & Co.ARQ 197

Phase 2 Study in Patients With MiT Tumors

Start: Oct 2007Est. completion: Feb 201147 patients
Phase 2Completed
NCT07181720Precision BioSciencesCD70-targeted CAR-T cells

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

Start: Sep 2025Est. completion: May 202890 patients
Phase 1Recruiting
NCT02837991Celldex TherapeuticsCDX-014

A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

Start: Jun 2016Est. completion: Nov 201816 patients
Phase 1Terminated
NCT00520533Heidelberg PharmaChimeric monoclonal antibody cG250

Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Start: Feb 2008Est. completion: Sep 20128 patients
Phase 1Terminated
NCT05410509Siemens HealthineersTrans-arterial embolization

"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"

Start: Jan 2024Est. completion: Dec 2027
N/ARecruiting
NCT04375150PfizerTyrosine kinase inhibitor

Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC

Start: Dec 2019Est. completion: Oct 2022355 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 516 patients
6 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)